Lineage to Present at 2024 BIO International Convention

Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company, announced that CEO Brian M. Culley will present at the 2024 BIO International Convention on June 4, 2024, at 2:30 pm in Theater 3.

The company will also engage in meetings with potential partners to explore strategic alliances for its cell therapy transplant programs.

The BIO International Convention, the world's largest biotech industry gathering, will take place from June 3-6, 2024, at the San Diego Convention Center.

Positive

• CEO Brian M. Culley's presentation at a prominent event can boost visibility.
• Meetings with potential partners may lead to strategic alliances.
• Participation in the world’s largest biotech event enhances industry credibility.

Negative

• No new financial data or clinical results were announced.
• Potential for high expenses related to attending and hosting meetings at the convention.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention, on Tuesday June 4^th, 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage’s novel pipeline of cell therapy transplant programs. The BIO International Convention is the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

About BIO

BIO is the world’s largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product, to Fortune 500 multinationals. BIO also represents state and regional biotech associations, service providers to the industry, and academic centers. Our members help foster a healthy economy by creating good-paying, biotechnology jobs. We also host the largest cost-savings program in the life sciences industry, BIO Business Solutions, which saves nearly $700 million in aggregate for 4,500+ companies every year. For more information visit www.bio.org or follow the organization on X/Twitter @IAmBiotech.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530288523/en/

Lineage Cell Therapeutics, Inc. IR

Ioana C. Hone

(ir@lineagecell.com)

(442) 287-8963

LifeSci Advisors

Daniel Ferry

(daniel@lifesciadvisors.com)

(617) 430-7576

Russo Partners – Media Relations

Nic Johnson or David Schull

(Nic.johnson@russopartnersllc.com)

(David.schull@russopartnersllc.com)

(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

FAQ

When will Lineage Cell Therapeutics present at the 2024 BIO International Convention?

Lineage Cell Therapeutics will present on June 4, 2024, at 2:30 pm.

What is the stock symbol for Lineage Cell Therapeutics?

The stock symbol for Lineage Cell Therapeutics is LCTX.

Where is the 2024 BIO International Convention taking place?

The 2024 BIO International Convention will take place at the San Diego Convention Center.

What will Lineage Cell Therapeutics discuss at the 2024 BIO International Convention?

Lineage Cell Therapeutics will discuss opportunities for strategic alliances for its cell therapy transplant programs.

Who is the CEO of Lineage Cell Therapeutics?

The CEO of Lineage Cell Therapeutics is Brian M. Culley.